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Abstract
Abnormal autophagy has become a central thread linking neurodegenerative diseases, particularly
of the motor neuron. One such disease is spinal muscular atrophy (SMA), a genetic neuromuscular
disorder caused by mutations in the SMN1 gene resulting in low levels of Survival Motor Neuron
(SMN) protein. Despite knowing the causal protein, the exact intracellular processes that are
involved in the selective loss of motor neurons remains unclear. Autophagy induction can be
helpful or harmful depending on the situation, and we sought to understand the state of the
autophagic response in SMA. We show that cell culture and animal models demonstrate induction
of autophagy accompanied by attenuated autophagic flux, resulting in the accumulation of
autophagosomes and their associated cargo. Expression of the SMN-binding protein a-COP, a
known modulator of autophagic flux, can ameliorate this autophagic traffic jam.
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Introduction
Spinal Muscular Atrophy (SMA) is a devastating inherited disorder caused by the loss of the
SMN1 gene responsible for production of the Survival Motor Neuron (SMN) protein (1) (2).
Low levels of this protein lead to dysfunction and degeneration of alpha motor neurons,
muscle wasting and eventually death in the more severe forms. Understanding the processes
by which these motor neurons fail and the timing of that failure increases our understanding
of the disease state. Such information may educate therapeutic decisions. One cellular
process, macroautophagy, has come to the forefront in motor neuron diseases as a common
pathology present in degenerating motor neurons. Further study of the onset of autophagy
and the dynamics of the autophagic pathway in SMA will allow for the potential therapeutic
intervention, as pharmacological manipulation of this system is well understood.
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Macroautophagy, hereafter referred to as autophagy, is responsible for the degradation of
cytoplasmic proteins and organelles by incorporation into a double-membrane vesicle that is
transported to the lysosome for degradation (3). This process appears to be dysregulated in a
number of neurodegenerative conditions; typically becoming hyper-activated in an attempt
to preserve cellular function or remove damaged cellular material such as at the axon
terminal following injury. In other cases such as Alzheimer’s disease, Huntington’s disease
or aging, the normal autophagic flux slows, resulting in a failure to clear the cell of obsolete
proteins and organelles (4). Tissue-specific knockout experiments in mice have highlighted
the importance of this pathway in neurons, demonstrating that loss of critical genes involved
in the execution of the autophagic pathway in the central nervous system results in profound
neurodegenerative disease (5, 6). Induction of autophagy has been reported in numerous
models of neurodegenerative disease, and may be a component of the cellular response to
depleted SMN levels (7). A recent report describes the accumulation of autophagosomes in
motor neuron cultures following depletion of SMN and in motor neurons cultures from
SMA mice (8). However, this study did not examine the dynamics of the autophagic
pathway in SMA model cells. Previous work in cultured cells has shown that depletion of
the SMN binding partner α-COP impaired autophagy resulting in an accumulation of
autophagosomes that failed to complete fusion with the lysosome (9). Autophagosome
accumulation can be a hallmark of induction of autophagy in response to general cellular
stress but can also result from ineffective intracellular trafficking and slow delivery of
autophagic vesicles to the lysosomal compartment. In fact, a recent publication
demonstrated that SMN-depleted NSC-34 cells, a motor neuron-like cell line, showed
impaired microtubule assembly and accumulation of mitochondria, both signs that normal
intracellular trafficking is disturbed in the absence of SMN (10).
In this report, we demonstrate that autophagic vesicles are present both in an inducible
NSC-34 cell culture model of SMA and in fibroblasts isolated from SMA patients. Using
live-cell imaging, we find that cells display a reduced autophagic flux when challenged
following SMN depletion. A nearly identical phenotype is seen in SH-SY5Y cells following
knockdown of the SMN binding partner α-COP., and expression of α-COP reduced the
number of autophagosomes in SMN-depleted NSC-34 cells. Finally, analysis of spinal cord
lysates from a severe mouse model of SMA shows accumulation of LC3-II protein as well
as an increase in p62 protein levels, indicating that dysregulated autophagy is a component
of SMA disease pathology in these animals.
Materials and Methods
Cell Culture
NSC-34 clone 4#56 (dox-inducible SMN shRNA) was described previously (Custer et al,
2013). Cells were maintained in DMEM with 10% Tet-system FBS and Pen/Strep. SMN
knockdown was induced with 2ug/ml doxycycline for 72hrs. Inducible alpha-COP
knockdown SH-SY5Y cells were described previously (11) and were maintained with
DMEM/F12 with 15% Tet-system FBS and Pen/Strep. Alpha-COP knockdown was induced
with 2ug/ml doxycycline for 72 hrs. Tert-immortalized SMA patient fibroblasts (3814T and
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3813T (13)) were maintained in SensiCell DMEM/F12 with 20% FBS supplemented with
Penn/Strep and 0.1ug/ml puromycin.
Lentiviral expression of FLAG-hSMN
The FLAG-SMN lentiviral vector was a gift from Dr. Xue-Jun Li (12). Virus was produced
in HEK-293TT cells co-transfected with Pax2 and MD2.G and supernatant was harvested at
48 and 72 hours. To concentrate the virus, supernatant was centrifuged at 20,000 rpm on a
20% sucrose cushion and resuspended in 1/10 the volume DMEM/10% FBS. Virus was
immediately added to NSC-34 cell cultures and cells were lysed after 48 hours for Western
blot analysis.
Immunofluorescence
eGFP-tagged rat LC3 was a gift from Dr T Yoshimori (13). The tandem-tagged LC3 flux
reporter was a gift from Dr. Paul Taylor(14). All cells were transfected using Lipofectamine
2000 (Invitrogen) at a ratio of 1:3. For staining of endogenous LC3 and p62, cultures were
grown on glass coverslips coated with either PDL (NSC-34 and SH-SY5Y) or collagen
(SMA fibroblasts). Cultures were fixed in 4% paraformaldehyde for 10 minutes, then
blocked/permeabilized in PBS with 5% normal goat serum and 1% TritonX-100 for 30
minutes. Rabbit polyclonal LC3 and p62 antibodies were purchases from Sigma and used at
1:300 and 1:1000 respectively at 4°C overnight. Anti-rabbit Alexa-488 was used at room
temperature for 1 hour at 1:1000. Coverslips were sealed with VectaShield hard-set
mounting media with DAPI to visualize nuclei. For LC3 puncta counts, images were
captured at 100X, and the number of puncta per cell was determined in 50 cells per
experimental condition from 3 biological replicates for a total n=150 per condition using the
GFP-LC3 macro for ImageJ (created by Ruben Dagda). Puncta per cell were compared by
two-tailed t-test. The experiment was repeated in triplicate with SMA patient fibroblasts
(3813T) compared to cells from an unaffected carrier (3814T) For live-cell imaging, cells
were plated onto glass-bottom 35 mm dishes. Following 48 hours of SMN knockdown, cells
were transfected with the tandem-tagged LC3 using Lipofectamine 2000. 20 hours post-
transfection, cultures were treated with rapamycin (0.5ug/ml) and switched to live-cell
imaging medium (5X stock pH 7.4 750 mM NaCl, 100 mM HEPES, 5 mM CaCl2, 25 mM
KCl, 5 mM Mg. On the day of use, this stock was diluted to 1X, supplemented with 95 mg
sucrose and 95 mg of albumin and sterile filtered. This experiment was performed on three
separate days with three different cultures, and a total of 45 controls and 52 SMN-depleted
cells were imaged using an Olympus FV1000 MPE with a Spectra-Physics 2-photon MaiTai
DeepSee laser, and the number of red and yellow puncta were counted. The percentage of
yellow puncta in control versus SMN-depleted cells was compared by one-tailed t-test. For
α-COP rescue experiments, NSC-34 cells were transfected with mCherry-tagged α-COP (a
gift from Dr. Wilfried Rossoll) and LC3-GFP and the number of puncta per cell was
quantified from three replicates.
Western Blotting
Cells and tissues were lysed in 8M urea lysis buffer (150 mM NaCl, 50 mM Tris, 1% NP40,
8M Urea supplemented with EDTA-free SigmaFast protease inhibitor cocktail). 20ug total
protein per lane was run on 4–15% TGX gradient gels (Biorad) and transferred to PVDF
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membranes. Rabbit polyclonal p62, and LC3 antibodies (Sigma) were used at 1:3000 and
1:10,000 respectively. Rabbit polyclonal SMN antibody (SantaCruz) was used at 1:1000.
Mouse monoclonal FLAG (M2) antibody and mouse monoclonal tubulin and actin
antibodies (Sigma) were used at 1:10,000 or 1:5000.
SMA model mice
SMA model mice (Jax stock number 005058) were bred following the scheme outlined by
the Didonato lab to produce litters that were 50% severe SMA and 50% phenotypically
normal (15). SMA pups were euthanized at postnatal day 7 and the spinal cords were
removed and rapidly homogenized in ice-cold 8M-urea lysis buffer. For western blot
analysis of p62, SMN and LC3 in PND7 animals, spinal cords were removed from n=6
normal and n=5 SMA pups from two separate litters.
Results
SMN depleted NSC-34 cells accumulate autophagic puncta
We selected the motor neuron-like hybrid cell line NSC-34 to model cellular pathology in
SMA. As we previously reported, we used a clonal line (NSC-34 4#56) expressing both the
reverse Tet transactivator and a Tet-responsive construct containing shRNA specific to
murine SMN (16). Following the addition of doxycycline, there is a robust knockdown of
SMN to an average of 47.4 +/− 10.9% of normal within 48 hours (Figure 1c). The cell line
quickly recovers normal levels of SMN protein following removal of the doxycycline. For
comparison and to determine any off-target effects of doxycycline, we maintain the NSC-34
clone #4 which expresses only the rTta plasmid but not the shRNA. This cell line is
hereafter referred to as #4. These tools allowed us to perform tightly controlled experiments
to analyze the consequences of SMN depletion. When viewed with light microscopy, we
observed that following SMN depletion, these cells became heavily vacuolated compared to
control cultures (not shown), and we hypothesized that the cells were undergoing autophagy.
To evaluate this, we transfected doxycycline-treated and control cultures with GFP-LC3.
Prior to incorporation into autophagosomes, GFP-LC3 displays diffuse cytoplasmic staining,
however after LC3I is lipidated to form LC3II and is incorporated in the autophagic vesicle
membrane, it appears as discrete puncta. Following fixation and fluorescent microscopy, the
number of puncta per cell was determined using the imageJ GFP-LC3 macro that was
created and characterized for the quantitative assessment of autophagic puncta in fluorescent
micrographs (17) (18). We could clearly visualize that SMN-depleted cultures had an
increase in GFP-LC3-positive puncta compared to control cultures in which LC3 staining
was mostly diffuse (Figure 1A, quantified in 1B). Puncta counts from 3 separate
experiments showed a significant increase in the number of LC3 puncta per cell in SMN-
depleted cultures by student’s t-test (54 +/− 14 puncta per cell compared to 9 +/− 6 in
control cultures, p<0.01). These changes are specific to SMN knockdown as doxycycline-
treated cultures from NSC-34 clone #4, which expresses the rTtA but not the SMN shRNA,
show no significant increase in the number of GFP positive puncta per cell (Figure 1b). LC3
conversion can also be visualized by Western blot as LC3-II migrates faster than LC3I.
Western blots of doxycycline-treated cultures show increased LC3-II compared to untreated
controls. These levels return to normal upon removal of doxycycline and resumption of
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normal SMN protein production (Figure 1c). Quantification of western blots from 3 separate
knockdowns followed by a 48 hour doxycycline washout shows that on average, p62
increased to 2.4 fold +/− 0.19 compared to controls (p<0.01 by student’s t-test) and LC3-II
increased to 1.46 fold +/− 0.08 compared to controls (p<0.05) (Figure 1d).
Reduced autophagic flux in SMN-depleted NSC-34 cells
The accumulation of LC3 positive puncta and the increase in LC3II protein indicate
induction of autophagy. However, we were interested in whether the reports of
compromised microtubule dynamics following knockdown of SMN would permit proper
progression through the autophagic pathway (10). LC3-II can also accumulate in cells where
the progression through the autophagic pathway and eventual fusion with the lysosome is
compromised. To distinguish between increase in autophagosome production and
diminished autophagic flux, we infected the cultures with retrovirus expressing dual-tagged
mRFP-LC3-GFP (19). This vector takes advantage of the fact that GFP fluorescence is
quenched in the acidic lysosomal compartment to separate early autophagosomes, which
have both red and green fluorescence and thus appear yellow, and autophagosome that have
successfully fused with the lysosome and appear red. As basal autophagy in the control
NSC-34 #4-#56 cultures is relatively low, all cultures were treated with the mTOR
antagonist rapamycin to induce maximal levels of autophagosome production. Using live-
cell confocal imaging, we observed that rapamycin-treated SMN knockdown cultures
contained an increased percentage of yellow puncta (55 +/− 14% compared to 27 +/− 10%
in control, p=0.027), indicating a failure to properly fuse with the lysosome (Figure 2A,
quantified in 2B). These data support our conclusion that altered microtubule dynamics
result in reduced autophagic flux in SMN-depleted NSC-34 cells.
Another method of examining autophagic flux is to assay for levels of the protein p62/
SQSTM1, which is degraded exclusively by autophagy (20). Accumulation of p62 indicates
reduced autophagic flux. Immunofluorescent labeling of NSC-34 #4-#56 cultures revealed a
statistically significant increase in the number of cells with p62-positive puncta following
SMN depletion (Figure 2E, quantified in 2F, p<0.05 by Student’s t-test). Western blot
analysis shows an increase in p62 protein levels in doxycycline-treated NSC-45 #4-#56
cultures accompanied by an increase in LC3-II. This profile returned to baseline when
cultures were infected with lentivirus expressing FLAG-tagged human SMN (21), which is
immune to the murine-specific shRNA construct in these cells (Figure 2C). D)
Quantification of Western blot analysis from repeated experiments shows that p62 increased
by 1.38 fold +/− 0.13 in SMN-depleted cultures compared to controls and returned to normal
(1.04 fold +/− 0.14) following the addition of FLAG-hSMN. LC3-II increased by 3.35 fold
+/− 0.57 in SMN-depleted cultures and rescue with FLAG-hSMN significantly reduced it to
1.82 fold +/− 0.32 compared to control cells (p<0.01 compared to doxycycline-treated cells
alone).
LC3-positive puncta accumulate in SMA patient fibroblasts
To determine whether our findings were a more general result of SMN depletion and not
unique to our NSC-34 model, we transfected telomerase-immortalized SMA-derived human
fibroblasts (line 3813T) (22) and with LC3-GFP and compared the number of GFP-positive
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puncta to cells from an unaffected heterozygous parent (line 3814T). As shown in Figure 3,
we observe an increase in LC3-positive puncta compared to controls (Figure 3A).
Quantification of the number of GFP-positive puncta per cell from three separate fibroblast
cultures show that SMA cells have a statistically significant increase in the number of
puncta per cell (p<0.01 by Student’s t-test). Western blot analysis from these cells shows an
increase in p62 and LC3-II proteins, consistent with the poor flux seen in our NSC-34 cell
model although these cells were not amenable to live-cell imaging with the flux reporter
construct. Quantification of repeated Western blots shows that p62 levels increase to 1.5 fold
+/− 0.13 compared to controls and LC3-II increased to 2.32 fold +/− 0.59 (p<0.05 for both
by Student’s t-test).
Markers of autophagy in a severe mouse model of SMA
We moved on from these cell culture models to examine the profile of autophagy markers in
the so-called “Taiwanese” mouse model of SMA. These animals carry the ‘Hung’ targeted
deletion of murine SMN as well as a human SMN2 transgene (23). In this model, animals
that are SMN null and heterozygous for SMN2 die around 12 days with profound muscle
wasting, weakness and loss of righting reflex. We chose to examine autophagy markers at
postnatal day 7. At this age, the SMA pups are significantly smaller than their
phenotypically normal siblings (2.5g +/− 0.7 compared to 3.8g +/− 0.5). The animals are
still mobile but show a delayed righting reflex compared to their normal littermates (not
shown). Their relative mobility insures that they are still gaining access to milk, preventing
any potential autophagy induction due to poor nursing following the onset of major motor
coordination losses. Similar to what we detect in the NSC-34 cells, spinal cord lysates from
SMA pups show increases in p62 and in LC3-II relative to LC3-1 by Western blotting
(Figure 5A). Quantification of Western analysis from multiple spinal cords isolated from
two separate litters shows that in SMA mice p62 increase 2.09 fold +/− 0.41 compared to
heterozygous littermates and LC3-II increased to 2.21 fold +/− 0.25 (Figure 5B, p<0.01 by
Student’s t-test for both p62 and LC3-II). Interestingly, we found that this was restricted to
the spinal cord. Muscle had a very modest increase in the ratio of LC3-II/I but no change in
the p62 levels and brain showed no change in either marker (not shown). These results
support our choice of the early time point, as we would expect starvation-induced autophagy
to be present in all three tissues if it were a confounding factor at this age.
The SMN binding partner α-COP regulates autophagy in SMN knockdown cells
We have shown that the COPI vesicle protein α-COP is an SMN binding protein and is able
to stimulate neurite outgrowth in SMN-depleted NSC-34 cells (11, 16). Loss of COPI
components (α, β or β′) in HeLa cells stably expressing the LC3-GFP autophagy reporter
resulted in accumulation of GFP positive puncta and failure to properly fuse with the
lysosome (9). We previously published an inducible α-COP knockdown line of SH-SY5Y
cells (11). Following induction of α-COP knockdown with doxycycline (2ug/ml), we
confirm a robust decrease in the levels of α-COP protein and a modest decrease in ε-COP,
most likely due to destabilization of the α/β/ε subcomplex (Figure 5A). Immunofluorescent
staining for endogenous LC3 in these cultures shows a significant increase in the number of
cells with LC3 puncta (Figure 5B). Western blots reveal an increase in the accumulation of
LC3-II compared to LC3-1 in knockdown cultures consistent with the immunofluorescent
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findings (Figure 5A). We previously reported that over-expression of α-COP rescues neurite
outgrowth in SMN-depleted NSC-34 cells (16). To determine whether over-expression of α-
COP would restore normal autophagic trafficking, we co-transfected mCherry-tagged α-
COP with LC3-GFP into NSC-34 4#56 cultures with and without doxycycline.
Immunofluorescence analysis shows that cells containing α-COP have significantly fewer
GFP-positive puncta than SMN-depleted cells (28 +/− 9 puncta per cell compared to 49 +/−
11 with doxycycline alone, p=0.033 by Student’s t-test), but do not fully restore levels to
normal (Figure 5C, D). Western blotting shows that expression of α-COP does not interfere
with the SMN knockdown, but does shift the levels of p62 and the ratio of LC3-II/I towards
normal although it does not completely rescue (Figure 5E). Quantitation of multiple Western
blots showed that expression of FLAG-α-COP significantly reduces the increase of p62
from 2.04 fold +/− 0.31 in cells treated with doxycycline alone to 1.38 fold +/− 0.11
(p=0.026 by Student’s t-test).
Discussion
The autophagic pathway is an important part of neuronal homeostasis that provides cells
with an opportunity to restore their cellular environment by removing aged protein and
organelles. Under routine culture conditions, autophagy is constitutively active in neuronal
cells to maintain a healthy micro-environment (24). Perturbations in the smooth progression
through this pathway may accelerate accumulation of autophagosomes and their associated
cargoes. The importance of proper autophagic clearance in motor neuron diseases has
recently been highlighted by work in amyotrophic lateral sclerosis (ALS). Autophagosomes
were detected in spinal cords of sporadic ALS patients (25) as well as in mouse models of
hereditary ALS caused by mutations in superoxide dismutase 1 (SOD1) (26). In mice, these
accumulations begin long before the onset of measurable symptoms (27). Evidence in
NSC-34 cells indicated that SOD1 aggregates could be cleared by activation of autophagy,
giving rise to the idea that the motor neurons could be rescued by forced clearance of SOD1
(28).
Whether autophagy is a viable therapeutic target in motor neuron disease remains unclear.
The relatively well-tolerated drugs rapamycin and hydroxychloroquine have been shown to
induce and inhibit autophagy respectively, but whether pharmacological manipulation of
autophagy in SMA would be beneficial is unclear. In mouse models of ALS, genetic
alterations that modulate autophagy lead to clearing of SOD1 aggregates and delay of
symptom onset (29, 30). Similarly, expression of BCL-XL rescued motor neurons from
SMA mice, possibly by interactions with Beclin-1 (31). Unfortunately, ALS mouse models
treated with rapamycin actually progressed much more rapidly, most likely due to an
intracellular traffic jam created by forced induction of autophagy in the face of reduced
autophagic flux, which would account for the increased levels of p62 protein that were
detected in these animals (32). In a very small pilot study, mice from the SMN delta7 model
(33) were treated with rapamycin beginning at postnatal day 1. These animals died before
vehicle treated siblings (C. Lorson and E. Osman, personal communication). Additionally,
although it has been reported that SMN is normally cleared by the proteasome following
ubiquitination (34), in our HEK293 cell based SMN-luciferase reporter assay we find a
decrease in SMN2-derived full-length SMN protein in cells treated with rapamycin (not
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shown). Therefore, we may be seeking an elusive autophagic “sweet spot” that encourages
proper cellular clearance without depleting the minimal amounts of SMN protein provided
by the SMN2 gene.
Recent advances have developed a number of rapamycin analogues with improved
bioavailability and solubility profiles (35, 36). These new compounds are able to specifically
inhibit both mTORC1 and 2 and produce a more robust activation of the autophagic
pathway. These newer compounds may be able to stimulate sufficient levels of autophagy to
overcome the apparent deficits in flux and allow for motor neurons to clear accumulated and
potentially toxic damaged organelles as well as use these recycled cellular components as an
additional energy source in the face of SMA-induced stress. Another inducer of autophagy is
sodium valproate, which acts on the autophagy pathway by reducing inositol and IP3 levels
(37). Although the results in clinical trials have been inconclusive, valproic acid is known to
increase survival in SMA mouse models (38).
The more we learn about the nature of the autophagic dysregulation in SMA, its onset and
pathology, the more we can gauge whether the pharmacological tools we have available for
modulating autophagy in the clinical setting may have beneficial effects.
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Figure 1. SMN knockdown in NSC-34 cells induces autophagy
Clonal NSC-34 cells expressing a doxycycline-inducible shRNA against murine SMN
(clone #4-56) were treated with doxycycline (2ug/ml) for 48 hours to deplete SMN levels to
47.4 +/− 10.9% relative to controls (inset in A shows Western blot of SMN levels following
48hr knockdown) and then transfected with GFP-LC3 to visualize autophagosomes. A)
Control cultures show mostly diffuse LC3-GFP fluorescence with very few autophagic
puncta per cell compared with Dox-treated cultures, which accumulate numerous GFP-
positive autophagic puncta. B) Quantification of the number of LC3-GFP puncta per cell
shows a that SMN-depleted cells have a statistically significant increase in puncta by
Student’s t-test compared to control cultures (p<0.05). No increase in autophagic puncta was
observed when cells from clone #4, which express only the rTta plasmid, were treated with
doxycycline. C) Western blotting for LC3 shows that following SMN knockdown, the ration
of LC3-II/LC3-I increases. Removal of doxycycline for 48 hrs allows SMN levels and LC3
ratios to return to normal. D) Quantitative analysis of repeated Western blots shows a
significant increase in LC3-II protein following SMN depletion (p<0.05 by Student’s t-test).
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Figure 2. SMN depletion reduces autophagic flux
NSC-34 #4-#56 cells were treated with doxycycline for 48 hrs to induce SMN knockdown,
and then transfected with mCherry-eGFP-LC3. Control and SMN-depleted cultures were
treated with rapamycin to induce autophagy and live-cell confocal micrographs were
captured to visualize total autophagosomes (yellow) compared to autophagosomes that had
successfully fused with the lysosome (red). A) SMN knockdown cells display significantly
increased number of yellow puncta (merged image) compared to controls (p=0.027 by
Student’s t-test), indicating a reduced rate of autophagic flux (quantified in B). C) Western
blot analysis demonstrates increased p62 and LC3-II, which is restored to normal by
infection with lentivirus expressing FLAG-hSMN. D) Quantitative analysis of repeated
Western blots shows a statistically significant increase in p62 and LC3-II protein levels by
Student’s t-test following SMN knockdown. E) Staining for endogenous p62 in SMN-
depleted cultures shows an increase in the number of cells with bright p62 puncta
(quantified in F, p<0.05 by Student’s t-test).
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Figure 3. Autophagy is disturbed in SMA patient fibroblasts
SMA-derived fibroblasts (3813T) were compared to fibroblasts from an unaffected parent
(3814T). A) Transfection with LC3-GFP shows increased GFP-positive autophagic puncta
per cell in SMA cells compared to controls (quantified in B). C) Western blot analysis
reveals a profile similar to SMN-depleted NSC-34 cells with accumulation of both p62 and
LC3-II. D) Quantitative analysis of repeated Western blots shows the increases in p62 and
LC3-II in SMA fibroblasts are statistically significant compared by Student’s t-test (p<0.05).
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Figure 4. Autophagy in a mouse model of SMA
A) Western blot analysis of spinal cords from the severely affected Taiwanese SMA mouse
model taken at post-natal day 7 shows accumulation of p62 and an increase in LC3-II/I
ratios. B) Quantitative analysis of repeated Western blots from multiple SMA litters shows a
statistically significant increase in both p62 and LC3-II protein levels in SMA pups
compared to heterozygous littermates (p<0.01 by Student’s t-test).
Custer and Androphy Page 14
Mol Cell Neurosci. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. α-COP modulates autophagic flux
A) Western blotting after 48 hours of doxycycline treatment reveals robust reduction of α-
COP and εCOP and an increase in LC3-II/I. B) Staining for endogenous LC3 in SH-SY5Y
cells after doxycycline-induced α-COP knockdown shows an increase in the number of cells
with LC3-positive puncta compared to untreated control cultures. C) Transfection of
mCherry α-COP reduced the number of LC3-GFP puncta per cell in SMN knockdown
cultures compared to SMN knockdown alone (quantified in D, p<0.05 by Student’s t-test).
E) Western blot analysis of SMN-depleted NSC-34 cultures with and without FLAG-α-COP
shows a reduction in p62 accumulation and LC3II/I ratios to normal levels. F) Quantitation
of repeated Western blots shows that FLAG-α-COP restores p62 and LC3-ii protein levels
to normal (1.38 fold +/− 0.11 for p62 relative to untreated controls and 1.21 +/− 0.14 for
LC3-II).
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